Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis
- First Online:
- Cite this article as:
- Montella, L., Merola, C., Merola, G. et al. J Bone Miner Metab (2009) 27: 110. doi:10.1007/s00774-008-0001-2
Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.